Research ArticleTheranostics
Open Access
Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
Daniel A. Pryma, Bennett B. Chin, Richard B. Noto, Joseph S. Dillon, Stephanie Perkins, Lilja Solnes, Lale Kostakoglu, Aldo N. Serafini, Miguel H. Pampaloni, Jessica Jensen, Thomas Armor, Tess Lin, Theresa White, Nancy Stambler, Stuart Apfel, Vincent A. DiPippo, Syed Mahmood, Vivien Wong and Camilo Jimenez
Journal of Nuclear Medicine May 2019, 60 (5) 623-630; DOI: https://doi.org/10.2967/jnumed.118.217463
Daniel A. Pryma
1Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Bennett B. Chin
2Department of Radiology–Nuclear Medicine, University of Colorado Anschutz Medical Campus, Denver, Colorado
Richard B. Noto
3Division of Nuclear Medicine, Rhode Island Hospital/Warren Alpert Medical School of Brown University, Providence, Rhode Island
Joseph S. Dillon
4Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa
Stephanie Perkins
5Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
Lilja Solnes
6Department of Radiology and Radiological Science, Johns Hopkins Medicine, Baltimore, Maryland
Lale Kostakoglu
7Department of Nuclear Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
Aldo N. Serafini
8Division of Nuclear Medicine, University of Miami School of Medicine, Miami, Florida
Miguel H. Pampaloni
9Department of Radiology and Biomedical Imaging, University of California at San Francisco School of Medicine, San Francisco, California
Jessica Jensen
10Department of Research and Development, Progenics Pharmaceuticals, Inc., New York, New York; and
Thomas Armor
10Department of Research and Development, Progenics Pharmaceuticals, Inc., New York, New York; and
Tess Lin
10Department of Research and Development, Progenics Pharmaceuticals, Inc., New York, New York; and
Theresa White
10Department of Research and Development, Progenics Pharmaceuticals, Inc., New York, New York; and
Nancy Stambler
10Department of Research and Development, Progenics Pharmaceuticals, Inc., New York, New York; and
Stuart Apfel
10Department of Research and Development, Progenics Pharmaceuticals, Inc., New York, New York; and
Vincent A. DiPippo
10Department of Research and Development, Progenics Pharmaceuticals, Inc., New York, New York; and
Syed Mahmood
10Department of Research and Development, Progenics Pharmaceuticals, Inc., New York, New York; and
Vivien Wong
10Department of Research and Development, Progenics Pharmaceuticals, Inc., New York, New York; and
Camilo Jimenez
11Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M.D. Anderson Cancer Center, Houston, Texas
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 5
May 1, 2019
Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
Daniel A. Pryma, Bennett B. Chin, Richard B. Noto, Joseph S. Dillon, Stephanie Perkins, Lilja Solnes, Lale Kostakoglu, Aldo N. Serafini, Miguel H. Pampaloni, Jessica Jensen, Thomas Armor, Tess Lin, Theresa White, Nancy Stambler, Stuart Apfel, Vincent A. DiPippo, Syed Mahmood, Vivien Wong, Camilo Jimenez
Journal of Nuclear Medicine May 2019, 60 (5) 623-630; DOI: 10.2967/jnumed.118.217463
Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
Daniel A. Pryma, Bennett B. Chin, Richard B. Noto, Joseph S. Dillon, Stephanie Perkins, Lilja Solnes, Lale Kostakoglu, Aldo N. Serafini, Miguel H. Pampaloni, Jessica Jensen, Thomas Armor, Tess Lin, Theresa White, Nancy Stambler, Stuart Apfel, Vincent A. DiPippo, Syed Mahmood, Vivien Wong, Camilo Jimenez
Journal of Nuclear Medicine May 2019, 60 (5) 623-630; DOI: 10.2967/jnumed.118.217463
Jump to section
Related Articles
Cited By...
- Metastatic paraganglioma presenting with spinal cord compression requiring urgent surgery
- Efficacy and Safety of 124I-MIBG Dosimetry-Guided High-Activity 131I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma
- Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of meta-Iodobenzylguanidine
- Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma
- Managing a High-Specific-Activity Iobenguane Therapy Clinic: From Operations to Reimbursement
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
- Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities
- Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
- Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma
- High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
- Effects of Repeated 131I-Meta-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors
- A Mighty Oak Forest from a Single, Well-Planted Acorn (perspective on "Radiolabeled Adrenergic Neuron-Blocking Agents: Adrenomedullary Imaging with [131I] Iodobenzylguanidine" J Nucl Med. 1980;21:349-353)
- Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright
- Comprehensive review of evaluation and management of cardiac paragangliomas
- Phase 2 study of pembrolizumab in patients with advanced rare cancers
- Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
- NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
- The Future of Nuclear Medicine as an Independent Specialty